References
- A. A. Soderholm, P. T. Lehtovuori, and T. H. Nyronen, Three-dimensional structure-activity relationships pf nonsteroidal ligands in complex with androgen receptor ligand-binding domain, J. Med. Chem., 48(4), 917 (2005). https://doi.org/10.1021/jm0495879
- S. M. Singh, S. Gauthier, and F. Labrie, Androgen receptor antagonists (antiandrogens): structure-activity relationships, Curr. Med. Chem., 7(2), 211 (2000). https://doi.org/10.2174/0929867003375371
- L. Zhi and E. Martinborugh, Chapter 17, Selective androgen receptor modulators (SARMS), Ann. Rep. Med. Chem., 36, 169 (2001).
- J. T. Dalton, A. Mukherjee, Z. Zhu, L. Kirkovsky, and D. D. Miller, Discovery of nonsteroidal androgens, Biochem. Biophys. Res. Commun., 244(1), 1 (1998). https://doi.org/10.1006/bbrc.1998.8209
- J. J. Morris, L. R. Hughes, A. T. Glen, and P. J. Taylor, Non-steroidal antiandrogens. Design of novel compounds based on an infrared study of the dominant conformation and hydrogen-bonding properties of a series of anilide antiandrogens, J. Med. Chem., 34(1), 447 (1991). https://doi.org/10.1021/jm00105a067
- S. Yamamoto, N. Matsunaga, T. Hitaka, M. Yamada, T. Hara, J. Miyazaki, T. Santou, M. Kusaka, M. Yamaoka, N. Kanzaki, S. Furuya, A. Tasaka, K. Hamamura, and M. Ito, Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists, Bioorg. Med. Chem., 20(1), 422 (2012). https://doi.org/10.1016/j.bmc.2011.10.067
- J. Liu, D. Obando, V. Liao, T. Lifa, and R, Codd, The many faces of the adamantyl group in drug design, Eur J Med Chem, 46(6), 1949 (2011). https://doi.org/10.1016/j.ejmech.2011.01.047
- J. C. Cho, H, S, Rho, Y. H, Joo, C. S. Lee, J. Lee, S. M. Ahn, J. E. Kim, S. S. Shin, Y. H. Park, K. D. Suh, and S. N. Park, Depigmenting activities of kojic acid derivatives without tyrosinase inhibitory activities, Bioorg. Med. Chem. Lett., 22(12), 4159 (2012). https://doi.org/10.1016/j.bmcl.2012.04.046
- A. M. Badger, J. N. Bradbeer, B. Votta, J. C. Lee, J. L. Adams and D. E. Griswold, Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function, J. Pharmacol. Exp. Ther., 279(3), 1453 (1996).